MORPHINE SULFATE (morphine sulfate) by Pfizer is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 1996.
Drug data last refreshed 1h ago
Morphine Sulfate is a full mu-opioid receptor agonist indicated for moderate to severe pain across acute, chronic, cancer, and postoperative settings, as well as neonatal abstinence syndrome and opioid use disorder. It works by binding to opioid receptors in the brain and spinal cord to produce analgesia without a ceiling effect. Dosing is titrated to effect and limited by adverse reactions including respiratory and CNS depression.
Product approaching loss of exclusivity with declining commercial momentum, suggesting smaller brand team and focus on transition planning rather than growth initiatives.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Worked on MORPHINE SULFATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Morphine Sulfate offers limited growth opportunities given its LOE-approaching lifecycle and minimal linked job openings, making it a consolidation rather than expansion role. Career advancement may be constrained unless involvement includes leading LOE transition strategies, generic defense, or strategic partnerships.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo